Regional features of the cystic fibrosis pediatric population structure and pathogenetic therapy coverage with CFTR-modulators in the Southern Federal District of the Russian Federation

Introduction. Cystic fibrosis (CF) remains one of the most significant inherited multisystem diseases of childhood, characterized by progressive damage to the bronchopulmonary system, exocrine pancreatic insufficiency, and marked clinical phenotype variability governed by both underlying genotype and the timing of pathogenetic therapy initiation. Recently, the advent of CFTR-modulators dramatically changed the paradigm of CF management, as it has become possible for the first time to address the molecular defect underlying the disease, rather than just its clinical manifestations.

Aim. To analyze the regional structure of the CF patient population in the Southern Federal District (SFD) and assess the coverage of the pediatric cohort with targeted therapy.

Materials and methods. A descriptive analysis was conducted using the regional data on CF patients in the SFD. The following parameters were assessed: the number of patients, patient distribution across the SFD entities, the number of newly diagnosed cases in 2025, the volume of patient referrals to the therapeutic facilities, availability of CFTR-modulators, and prescription profiles.

Results. The SFD CF population was estimated at 521 patients, with 366 children and 155 adults. The Krasnodar Territory, Rostov Region, Republic of Crimea, and Volgograd Region had the largest cohorts of CF patients. In 2025, 20 new cases of the disease were diagnosed in the district, as compared with the expected number of 25–30, calculated from population-based data on the average incidence of CF in the Russian Federation. 246 children received targeted therapy, while 120 patients remained without pathogen-oriented treatment. Among targeted drugs dominated the triple combination composed of elexacaftor, tezacaftor, and ivacaftor introduced to the Russian market under the trade name Trilexa® (Tuteur S.A.C.I.F.I.A., Argentina) (78%) and Trikafta® (Vertex Pharmaceuticals) (15.9%).

Conclusions. The available data show a signficant progress in the availability of pathogen-oriented therapy in the SFD, but there remain genetic, age-related, and institutional barriers limiting full patient coverage with highly effective CFTR-modulators. The regional analysis highlights the need for further improvements in the neonatal screening system, expansion of genotypeoriented therapy, and continuity of medical care for adolescents and young adults.

1. Авдеев СН, Аветисян ЛР, Амелина ЕЛ, Баранов АА, Баранова ИА, Басова АЯ и др. Кистозный фиброз (муковисцидоз): клинические рекомендации. М.; 2025. 305 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/372_3.

2. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021:397(10290):2195–2211. https://doi.org/10.1016/S0140-6736(20)32542-3.

3. Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65–124. https://doi.org/10.1016/S2213-2600(19)30337-6.

4. Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023;402(10408):1171–1184. https://doi.org/10.1016/S0140-6736(23)01609-4.

5. Kondratyeva EI, Odinaeva ND, Zhekaite EK, Pasnova EV, Fatkhullina IR, Maksimycheva TYu et al. Efficacy of CFTR modulators in clinical practice (6-month follow-up). Pulmonologiya. 2023;33(2):189–197. (In Russ.) https://doi.org/10.18093/0869-0189-2023-33-2-189-197.

6. Kondratyeva EI, Avdeev SN, Kutsev SI. New possibilities for targeted therapy of cystic fibrosis. Pulmonologiya. 2025;35(2):167–176. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-2-167-176.

7. Perrotta N, Fiorito LA, Gentile R, Vescovo R, Piciocchi A, Troiani P et al. RealWorld Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/ Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study. Clin Transl Sci. 2025;18(10):e70373. https://doi.org/10.1111/cts.70373.

8. Kutsev SI, Izhevskaya VL, Kondratyeva EI. Targeted therapy for cystic fibrosis. Pulmonologiya. 2021;31(2):226–236. (In Russ.) https://doi.org/10.18093/0869-0189-2021-31-2-226-236.

9. Goetz DM, Savant AP. Review of CFTR modulators 2020. Pediatr Pulmonol. 2021;56(12):3595–3606. https://doi.org/10.1002/ppul.25627.

10. Амелина ЕЛ, Каширская НЮ, Кондратьева ЕИ, Красовский СА, Старинова МА, Воронкова АЮ, Гинтер ЕК (ред.). Регистр пациентов с муковисцидозом в Российской Федерации. 2023 год. М.: МЕДПРАКТИКА-М; 2025. 70 с. Режим доступа: https://ostrovaru.com/wp-content/uploads/2025/04/web_registre_2023-na-sajty.pdf.

11. Kondratyeva EI, Voronkova AYu, Fatkhullina IR, Orlov AV, Pyaterkina OG, Protasova TA, Psyurnikova OS. Study of the efficacy and safety of the generic drug ivacaftor + tezacaftor + elexacaftor/ivacaftor (trade name Trilexa®). Pulmonologiya. 2025;35(6):832–843. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-6-832-843.

12. Zolin A, Adamoli A, Zomer D, Fox A, Krasnyk M, Lorca Mayor S et al. ECFSPR 2024 Annual Data Report. Zenodo; 2026. 153 p. https://doi.org/10.5281/zenodo.20085096.

13. Abdulrahem N, Cheng S, Eckford P, Stephenson A, Stanojevic S, Sykes J. 2022 Annual Data Report. The Canadian Cystic Fibrosis Registry. Toronto, Canada: Cystic Fibrosis Canada; 2023. 56 p. Available at: https://www.mouthmedia.com/wp-content/uploads/2025/01/2022AnnualDataReport-WEB.pdf.

14. Naito Y, Adams F, Charman S, Duckers J, Davies G, Clarke S. 2023 Annual Data Report. UK Cystic Fibrosis Registry. London: Cystic Fibrosis Trust; 2024. 90 p. Available at: https://www.cysticfibrosis.org.uk/sites/default/files/2024-11/CFT_2023_Annual_Data_Report_Oct2024%201.pdf.

15. Pollak M, Gambazza S, Orenti A, De Rose V, Prais D, Kerem E, Mei Zahav M. Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry. ERJ Open Res. 2025;11(4):01248-2024. https://doi.org/10.1183/23120541.01248-2024.

16. Alicandro G, Zazzeron L, Visciola V, Bulfamante A, Biffi A, Corti F et al. Nutritional outcomes in people with cystic fibrosis receiving elexacaftor/ tezacaftor/ivacaftor: A 24-month real-world study. Nutrition. 2026;142:112984. https://doi.org/10.1016/j.nut.2025.112984.

17. Wilschanski M, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R et al. Highlights of the ESPEN-ESPGHAN-ECFS Guidelines on Nutrition Care for Infants and Children with Cystic Fibrosis. J Pediatr Gastroenterol Nutr. 2016;63(6):671–675. https://doi.org/10.1097/MPG.0000000000001349.

18. Turck D, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35(3):557–577. https://doi.org/10.1016/j.clnu.2016.03.004.

19. Linguiti G, Granberg V, Leonetti G, Lassandro G, Lassandro M, Delvecchio M, Giordano P. Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis. Biology. 2026;15(4):367. https://doi.org/10.3390/biology15040367.

20. Szentpetery SE. Evolving nutritional needs, obesity, and overweight status in cystic fibrosis. Curr Opin Pulm Med. 2023;29(6):610–614. https://doi.org/10.1097/MCP.0000000000001013.

21. Baran E, Pereyra B, Mattos L, Maracini M, Zattera E, D’Ascenzo M et al. Realworld experience with bioequivalent ETI formulations in adult cystic fibrosis patients: a prospective cohort study in Argentina. J Cyst Fibros. 2025;24(Suppl. 2):S212. https://doi.org/10.1016/S1569-1993(25)02000-4.

22. Tupayachi Ortiz M., Pereyra B, Baran E. Comparative clinical outcomes of Trikafta versus bioequivalent ETI formulations in the management of Cystic Fibrosis in adults: a real-world experience. J Cyst Fibros. 2025;24(Suppl. 2):S397. https://doi.org/10.1016/S1569-1993(25)02281-7.

23. Kondratyeva E, Melyanovskaya Y, Sherman V, Voronkova A, Zhekaite E, Krasovsky S et al. Study of the genetic and molecular epidemiology of cystic fibrosis based on the patient registry for planning targeted therapy in Russian Federation. Front Genet. 2024;15:1383033. https://doi.org/10.3389/fgene.2024.1383033.